MA32120B1 - Nouveaux composes chimiques - Google Patents

Nouveaux composes chimiques

Info

Publication number
MA32120B1
MA32120B1 MA32465A MA32465A MA32120B1 MA 32120 B1 MA32120 B1 MA 32120B1 MA 32465 A MA32465 A MA 32465A MA 32465 A MA32465 A MA 32465A MA 32120 B1 MA32120 B1 MA 32120B1
Authority
MA
Morocco
Prior art keywords
chemical compounds
new chemical
compounds
medicament
excessive
Prior art date
Application number
MA32465A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Ettmayer
Ioannis Sapountzis
Christian Klein
Andreas Mantoulidis
Steffen Steurer
Irene Waizenegger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32120(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32120B1 publication Critical patent/MA32120B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés chimiques de formule générale (1), dans laquelle les groupes r1 à r3, l sont défini tel que dans la revendication 1. Ces composés conviennent au traitement de maladies caractérisées par une prolifération excessive ou anormale de cellules et sont utilisés dans la préparation d'un médicament possédant les propriétés susmentionnées.
MA32465A 2007-07-02 2009-12-30 Nouveaux composes chimiques MA32120B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07111566 2007-07-02
PCT/EP2008/058433 WO2009003999A2 (fr) 2007-07-02 2008-07-01 Nouveaux composés chimiques

Publications (1)

Publication Number Publication Date
MA32120B1 true MA32120B1 (fr) 2011-03-01

Family

ID=38792475

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32465A MA32120B1 (fr) 2007-07-02 2009-12-30 Nouveaux composes chimiques

Country Status (21)

Country Link
US (1) US8889665B2 (fr)
EP (1) EP2173734B1 (fr)
JP (1) JP5511658B2 (fr)
KR (1) KR20100039849A (fr)
CN (1) CN101796045A (fr)
AR (1) AR067397A1 (fr)
AU (1) AU2008270300A1 (fr)
BR (1) BRPI0814601A2 (fr)
CA (1) CA2692383A1 (fr)
CL (1) CL2008001943A1 (fr)
CO (1) CO6251316A2 (fr)
EA (1) EA201000105A1 (fr)
EC (1) ECSP099823A (fr)
IL (1) IL202625A0 (fr)
MA (1) MA32120B1 (fr)
MX (1) MX2009013935A (fr)
PE (1) PE20090837A1 (fr)
TN (1) TN2009000551A1 (fr)
TW (1) TW200911789A (fr)
UY (1) UY31198A1 (fr)
WO (1) WO2009003999A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501023A (zh) * 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2692379A1 (fr) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Nouveaux composes chimiques
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
EP2398797B1 (fr) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Dérivés des pyrimido[5,4-d]pyrimidine pour l'inhibition des tyrosine kinases
JP2010235575A (ja) * 2009-03-09 2010-10-21 Konica Minolta Holdings Inc 含窒素縮合複素環化合物の製造方法
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
WO2011117381A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Inhibiteurs de kinase b-raf
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2013018695A1 (fr) 2011-07-29 2013-02-07 武田薬品工業株式会社 Composé hétérocyclique
CN103172617A (zh) * 2011-12-20 2013-06-26 天津市国际生物医药联合研究院 1,5-二取代-1,2,3-三氮唑三氟甲基类化合物的应用
CN103539784B (zh) * 2012-07-09 2016-08-17 中国科学院广州生物医药与健康研究院 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143654A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
CN107709314A (zh) 2015-06-11 2018-02-16 巴斯利尔药物国际股份公司 外排泵抑制剂及其治疗性用途
KR101723881B1 (ko) * 2016-03-28 2017-04-07 이화여자대학교 산학협력단 신규한 트리아졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 오로라 키나제 관련 약학적 조성물
WO2020007729A1 (fr) * 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Dérivés de triazole benzamide en tant qu'agonistes de gpr142
JP2023524563A (ja) * 2020-05-07 2023-06-12 ラムバム メド－テック リミテッド Ａｐｏｌ１－関連疾患の治療に使用するための組成物
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
JP2025513456A (ja) * 2022-04-19 2025-04-24 ウォーターシェッド メディカル インコーポレイテッド 泌尿器系障害を処置するための製剤
CN114805334B (zh) * 2022-05-24 2023-06-09 深圳大学 一种QC和GSK-3β多靶向抑制剂及其制备方法与应用
EP4648851A1 (fr) * 2023-01-10 2025-11-19 Astrazeneca AB (hétéro)anilines substituées et leur utilisation
CN116068110B (zh) * 2023-01-19 2024-11-22 武汉大学 叠氮质谱探针的合成方法及应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU507066B1 (en) 1977-09-06 1980-01-31 Sumitomo Chemical Company, Limited 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja) 1989-09-20 1991-07-29 Fuji Photo Film Co Ltd カラー画像形成方法
DK0808312T3 (da) 1995-02-02 2001-02-12 Smithkline Beecham Plc Indolderivater som 5-HT-receptorantagonist
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US6492403B1 (en) 1999-02-09 2002-12-10 3-Dimensional Pharmaceuticals, Inc. Methods of treating C1s-mediated diseases and conditions and compositions thereof
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2002069070A (ja) * 2000-04-07 2002-03-08 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2003037274A2 (fr) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides et -sulfonamides
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
ATE329909T1 (de) 2002-11-27 2006-07-15 Boehringer Ingelheim Pharma 1,2,3-triazolamid-derivate als cytokininhibitoren
WO2005023761A2 (fr) 2003-09-11 2005-03-17 Kemia, Inc. Inhibiteurs des cytokines
WO2005030705A1 (fr) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005040152A1 (fr) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Azolecarboxamides substitues par heterocyclylphenyle et heterocyclylpyridile
ATE501128T1 (de) * 2003-12-03 2011-03-15 Boehringer Ingelheim Pharma 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
PT1725544E (pt) 2004-03-09 2009-07-02 Boehringer Ingelheim Pharma 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
WO2006053227A2 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes modulateurs de la il-12
EP1858877B1 (fr) * 2005-01-14 2014-03-12 Gilead Connecticut, Inc. Urées à substitution 1,3-diaryle, modulateurs de l'activité de kinases
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (fr) 2005-11-02 2007-05-18 Kemia, Inc. Inhibiteurs de cytokine bisamide
WO2007075896A2 (fr) 2005-12-22 2007-07-05 Kemia, Inc. Inhibiteurs de cytokine heterocycliques
US20070155746A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
US7858804B2 (en) 2006-04-18 2010-12-28 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
WO2008008234A1 (fr) 2006-07-07 2008-01-17 Targegen, Inc. Inhibiteurs de type 2-amino-5-substituant-pyrimidines
WO2008005570A1 (fr) 2006-07-07 2008-01-10 Schering Corporation Cyclobutène-1,2-diones 3,4-disubstituées utilisées comme ligands de récepteur de chimiokine cxc
CN101501023A (zh) 2006-07-07 2009-08-05 贝林格尔.英格海姆国际有限公司 苯基取代的杂芳基衍生物及其作为抗肿瘤剂的用途
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2008089034A2 (fr) 2007-01-11 2008-07-24 Kemia, Inc. Inhibiteurs de cytokine
CA2679659C (fr) 2007-03-01 2016-01-19 Novartis Ag Inhibiteurs de pim kinase et procedes de leur utilisation
CL2008001943A1 (es) 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CA2692379A1 (fr) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Nouveaux composes chimiques
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
PT2324008E (pt) 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inibidores da proteína quinase
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
EP2398797B1 (fr) 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Dérivés des pyrimido[5,4-d]pyrimidine pour l'inhibition des tyrosine kinases
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Inhibiteurs de kinase b-raf
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
AR067397A1 (es) 2009-10-07
CL2008001943A1 (es) 2009-09-11
EA201000105A1 (ru) 2010-06-30
WO2009003999A2 (fr) 2009-01-08
CO6251316A2 (es) 2011-02-21
WO2009003999A3 (fr) 2009-07-16
JP5511658B2 (ja) 2014-06-04
TN2009000551A1 (fr) 2011-03-31
JP2010531851A (ja) 2010-09-30
IL202625A0 (en) 2010-06-30
EP2173734B1 (fr) 2016-03-23
MX2009013935A (es) 2010-01-28
CA2692383A1 (fr) 2009-01-08
US8889665B2 (en) 2014-11-18
PE20090837A1 (es) 2009-07-24
EP2173734A2 (fr) 2010-04-14
KR20100039849A (ko) 2010-04-16
AU2008270300A1 (en) 2009-01-08
US20110183952A1 (en) 2011-07-28
TW200911789A (en) 2009-03-16
UY31198A1 (es) 2009-01-30
ECSP099823A (es) 2010-01-29
BRPI0814601A2 (pt) 2019-09-24
CN101796045A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
MA32120B1 (fr) Nouveaux composes chimiques
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
MA30514B1 (fr) Nouveaux composes.
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
TN2013000349A1 (fr) Imidazo[5,1-f][1,2,4] triazines pour le traitement de troubles neurologiques
MA31447B1 (fr) Nouveaux dérivés d'acide dicarboxylique utilisés comme agonistes du récepteur s1p1
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
MA31841B1 (fr) Modulateurs du gpr40 à biphényle substitué
MA27697A1 (fr) Derive de phenethanolamine utilise dans le traitement des maladies respiratoires
TN2009000138A1 (fr) Biaryl-ether-urees
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA34898B1 (fr) Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
TN2009000450A1 (fr) Derives de pyridine
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA32656B1 (fr) Nouveaux composes chimiques
MY140187A (en) Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MA34308B1 (fr) Triazolopyridines substituées
MA30289B1 (fr) Dérivés d'amines
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a